Trial Profile
A post marketing study of Fantom
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Nov 2018
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- 31 Oct 2018 According to a REVA Medical media release, the first Fantom Encore has been implanted in this study
- 27 Aug 2018 New trial record
- 07 Aug 2018 According to a REVA Medical media release, the first patient was enrolled in May and the Company is working to add new hospitals to the study